Monitoring Thiopurine Metabolites in Korean Pediatric Patients with Inflammatory Bowel Disease

作者：Kim Mi Jin; Lee Soo Youn; Choe Yon Ho^*

来源：Yonsei Medical Journal, 2014, 55(5): 1289-1296.

DOI：10.3349/ymj.2014.55.5.1289

• Inflammatory bowel disease
• azathioprine
• thiopurine 5-methyltransferase
• 6-thioguanine nucleotide

Purpose: This study aimed to assess the role of thiopurine S-methyltransferase (TPMT) and 6-thioguanine nucleotide (6-TGN) as predictors of clinical response and side effects to azathioprine (AZA), and estimate the optimal AZA dose in Korean pediatric inflammatory bowel disease (IBD) patients. Materials and Methods: One hundred and nine pediatric IBD patients in whom AZA treatment was required were enrolled. Thiopurine metabolites were monitored since September 2010. Among them, 83 patients who had prescribed AZA for at least 3 months prior to September 2010 were enrolled and followed until October 2011 to evaluate optimal AZA dose, adverse effects and disease activity before and after thiopurine metabolite monitoring. Results: The result of the TPMT genotype was that 102 patients were *11 (wild type), four were *13C, one was *16, one was *116 (heterozygote) and one was *3C3C (homozygote). Adverse effects happened in 31 patients pre-metabolite monitoring and in only nine patients post-metabolite monitoring. AZA dose was 1.4 +/- 0.31 mg/kg/day before monitoring and 1.1 +/- 0.46 mg/kg/day after monitoring (p%26lt;0.001). However, there were no statistical differences in disease activity during metabolite monitoring period (p=0.34). Adverse effects noticeably decreased although reduction of the AZA dose since monitoring. Conclusion: TPMT genotype and thiopurine metabolite monitoring could be helpful to examine TPMT genotypes before administering AZA and to measure 6-TGN concentrations during prescribing AZA in IBD patients.

• 出版日期2014-9-1